Compare BOSC & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | AYTU |
|---|---|---|
| Founded | 1990 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 25.7M |
| IPO Year | 2002 | 2015 |
| Metric | BOSC | AYTU |
|---|---|---|
| Price | $5.05 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 45.5K | ★ 45.8K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $3.30 | $0.95 |
| 52 Week High | $6.72 | $3.07 |
| Indicator | BOSC | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 54.63 |
| Support Level | $4.58 | $2.14 |
| Resistance Level | $5.07 | $2.66 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 75.73 | 60.87 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.